Dr. Prat on the Differences Between EndoPredict and Prosigna

Aleix Prat, MD, PhD
Published: Monday, Jun 09, 2014

Aleix Prat, MD, PhD, medical oncologist, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the differences between EndoPredict and Prosigna.

Prat says the two tests both work from paraffin tissue, but use different technologies and have their own gene list. EndoPredict, a multi-gene test for breast cancer patients, uses RTPCR platform and 8 genes while Prosigna, the only breast cancer genomic assay powered by the innovation of PAM50, uses the nCounter NanoString platform and 50 genes.

There are only two genes that overlap between the two tests, Prat says. Both tests were also derived in different cohorts -- EndoProdict was developed from a cohort of patients with luminal disease treated with endocrine therapy while the Prosigna assay was developed in a cohort of patients with all subtypes and no adjuvant therapy.

Prat says Prosigna provides intrinsic subtype information and the risk of recurrence for each patient while EndoPredict only provides prognostic data.

Aleix Prat, MD, PhD, medical oncologist, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the differences between EndoPredict and Prosigna.

Prat says the two tests both work from paraffin tissue, but use different technologies and have their own gene list. EndoPredict, a multi-gene test for breast cancer patients, uses RTPCR platform and 8 genes while Prosigna, the only breast cancer genomic assay powered by the innovation of PAM50, uses the nCounter NanoString platform and 50 genes.

There are only two genes that overlap between the two tests, Prat says. Both tests were also derived in different cohorts -- EndoProdict was developed from a cohort of patients with luminal disease treated with endocrine therapy while the Prosigna assay was developed in a cohort of patients with all subtypes and no adjuvant therapy.

Prat says Prosigna provides intrinsic subtype information and the risk of recurrence for each patient while EndoPredict only provides prognostic data.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x